Fibrous Dysplasia Market Research Report- Forecast till 2027

Fibrous Dysplasia Market Information: By Diagnosis (X-Rays, CT Scans, MRI, Bone Scan, Biopsy), Treatment (Medication (Bisphosphonates, Intravenous Pamidronate), Surgical), End User (Hospitals & Clinics, Research Centers) - Forecast Till 2027

ID: MRFR/Pharma/3354-HCR | | Region: Global | 120 Pages         

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Fibrous Dysplasia Market, by Diagnosis

6.1 Introduction

6.2 X-rays

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 MRI

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 CT scans

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Biopsy

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Fibrous Dysplasia Market, by Treatment

7.1 Introduction

7.2 Surgery

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Medications

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Fibrous Dysplasia Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research centers

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Fibrous Dysplasia Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Bellicum Pharmaceuticals Inc

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 AVEO Pharmaceuticals Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bayer AG

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Merck & Co., Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Pfizer Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Fibrous Dysplasia Industry Synopsis, 2020-2027

Table 2 Global Fibrous Dysplasia Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Fibrous Dysplasia Market by Region, 2020-2027, (USD Million)

Table 4 Global Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 7 North America Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 12 US Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 16 South America Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Fibrous Dysplasia Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Fibrous Dysplasia Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Fibrous Dysplasia Market by End Users, 2020-2027, (USD Million)

 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Fibrous Dysplasia Market

Figure 3 Segmentation Market Dynamics for Fibrous Dysplasia Market

Figure 4 Global Fibrous Dysplasia Market Share, by Diagnosis 2020

Figure 5 Global Fibrous Dysplasia Market Share, by Treatment 2020

Figure 6 Global Fibrous Dysplasia Market Share, by End Users, 2020

Figure 7 Global Fibrous Dysplasia Market Share, by Region, 2020

Figure 8 North America Fibrous Dysplasia Market Share, by Country, 2020

Figure 9 Europe Fibrous Dysplasia Market Share, by Country, 2020

Figure 10 Asia Pacific Fibrous Dysplasia Market Share, by Country, 2020

Figure 11 Middle East & Africa Fibrous Dysplasia Market Share, by Country, 2020

Figure 12 Global Fibrous Dysplasia Market: Company Share Analysis, 2020 (%)

Figure 13 Amgen Inc: Key Financials

Figure 14 Amgen Inc: Segmental Revenue

Figure 16 Amgen Inc: Geographical Revenue

Figure 17 Bellicum Pharmaceuticals Inc: Key Financials

Figure 18 Bellicum Pharmaceuticals Inc: Segmental Revenue

Figure 19 Bellicum Pharmaceuticals Inc: Geographical Revenue

Figure 20 Novartis AG: Key Financials

Figure 21 Novartis AG: Segmental Revenue

Figure 22 Novartis AG: Geographical Revenue

Figure 23 AVEO Pharmaceuticals Inc: Key Financials

Figure 24 AVEO Pharmaceuticals Inc: Segmental Revenue

Figure 25 AVEO Pharmaceuticals Inc: Geographical Revenue

Figure 26 Merck & Co., Inc: Key Financials

Figure 27 Merck & Co., Inc: Segmental Revenue

Figure 28 Merck & Co., Inc: Geographical Revenue

Figure 29 Bayer AG: Key Financials

Figure 30 Bayer AG: Segmental Revenue

Figure 31 Bayer AG: Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue

Fibrous Dysplasia Market Speak to Analyst Request a Free Sample

Fibrous Dysplasia Market Scenario


Fibrous dysplasia is a rare and chronic bone disorder in which fibrous tissue develops in place of normal bone, weakens the affected bone, and deform or fracture it. As per reports from The Johns Hopkins University, the exact cause of fibrous dysplasia is unknown, but it is believed to be due to a chemical irregularity in a specific bone protein. This bone protein abnormality may arise due to a gene mutation present at birth, although it is not known to be an inherited disorder.


It often results in uneven growth of bones, pain, brittle bones, and bone deformity. In fibrous dysplasia, the most commonly affected bones includes femur (thighbone), tibia (shin bone), ribs, skull, facial bones, humerus (the bone of the upper arm), pelvis, vertebrae in the spine (less often).


The fibrous dysplasia market growth is majorly attributed to the increasing prevalence of the bone disorders. Moreover, some cases of fibrous dysplasia leads to cancer, which is likely to drive the market growth.


Currently, no cure is available for fibrous dysplasia. However, present treatment methods helps to prevent complications, such as recurrent bone fractures to help make the condition less severe.


According to reports from International Osteoporosis Foundation, Each year an estimated 1.5 million individuals suffer a fracture due to bone disease. The risk of a fracture increases with age and is more in women. Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into developing countries and emerging economies.


However, high cost of the current treatment methods and lack of alternative methods for the treatment of fibrous dysplasia may slow the market growth during the forecast period.


The fibrous dysplasia market is expected to grow at a CAGR of ~6.2 % during the forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure: Fibrous Dysplasia Market, By Region Market Share, 2016 (%)

Fibrous Dysplasia Market


Sources: Annual reports, Press release, White paper, Company presentation 


Segmentations


The fibrous dysplasia market is segmented on the basis by diagnosis, by treatment, and by end user.


On the basis of diagnosis, fibrous dysplasia market is segmented into X-rays, CT scans, MRI, bone scan, biopsy, and others.  


On the basis of treatment, fibrous dysplasia market is segmented into medications, surgical, and others. The medications is further segmented into bisphosphonates, intravenous (IV) pamidronate, calcitonin, raloxifene, and others


On the basis of the end user, fibrous dysplasia market is segmented into hospitals & clinics, research centers, and others.


Regional Analysis


The Americas dominate the fibrous dysplasia market owing to well-developed technology, increasing patient with bone disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the fibrous dysplasia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period.   


Asia Pacific is the fastest growing market owing to the presence of rapidly developing healthcare technology, increasing patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, may increase the market growth of the fibrous dysplasia in the region.   


On the other hand, the Middle East & Africa holds the least share of the fibrous dysplasia market due to limited screening, ignorance of diseases, and poor access to treatment, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Key Players


Some of key the players in the fibrous dysplasia market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp and others.


Research Methodology


Global Fibrous Dysplasia Market


Sources: Annual reports, Press release, White paper, and Company presentation


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.2 % (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of the bone disorders
  • Risk of a fracture increases with age and is more in women


  • Speak to Analyst Ask for Customization